What is the current stock price of Iovance Biotherapeutics, Inc. (IOVA)?

As of the latest market data, Iovance Biotherapeutics, Inc. (IOVA) is trading at $4.11. The stock has seen a gain of 11.08% today.

Does Iovance Biotherapeutics, Inc. (IOVA) pay a dividend?

Based on current data, Iovance Biotherapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Iovance Biotherapeutics, Inc.?

The current market capitalization of Iovance Biotherapeutics, Inc. (IOVA) is approximately unavailable.

IOVA

Iovance Biotherapeutics, Inc.·Healthcare

4.11

11.081%(+0.41)

Market Closed

4.10

0.243%(−0.01)

After Hours

Last Updated: — ET

52W L: $1.6652W H: $5.63

IOVA NEWS

globenewswire.com

19h ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif. , May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on May 21, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 93,340 shares of Iovance's common stock to thirteen new, non-executive employees.

globenewswire.com

19h ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 21, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 93,340 shares of Iovance's common stock to thirteen new, non-executive employees.

globenewswire.com

2d ago

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Fred Vogt, PhD, Interim CEO, President and General Counsel, and Corleen Roche, Chief Financial Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York, NY.

globenewswire.com

2d ago

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif. , May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Fred Vogt, PhD, Interim CEO, President and General Counsel, and Corleen Roche, Chief Financial Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.

zacks.com

May 8

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

seekingalpha.com

May 8

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. markets Amtagvi, a TIL therapy for advanced melanoma, and just reported Q1 earnings. Following Q1 results, IOVA shares declined over 13%, closing at $3.55, with a market cap of $1.59bn. The earnings announcement triggered a notable sell-off, reflecting investor concerns about near-term performance.

Company Profile

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Sector

Healthcare

Industry

Biotechnology

Employees

838

IPO Date

2010-10-15

Beta

0.69

Websitewww.iovance.com↗